The antiviral remdisivir doesn’t reduce viral lo
Post# of 148185
(Total Views: 529)
Posted On: 08/19/2020 10:22:18 AM
The antiviral remdisivir doesn’t reduce viral load or improve patient outcomes. It get a subset of patients (sick, it not too sick and without a bucket full of exclusion criteria) out of the hospital a few days early.
Leronlimab restores immune system, prevents clinical worsening, reverses symptom in three days and, reverses viremia.
And, just a few small points:
Leronlimab has no exclusion criteria.
Leronlimab is a SQ injection
Leronlimab met a designated endpoint without the whole of the FDA rushing to move the goal posts once Gilead had already kicked the ball.
I just realized why the FDA is slow walking Cytodyn. They are still exhausted from moving the goalposts for Gilead remdesevir trial.
Leronlimab restores immune system, prevents clinical worsening, reverses symptom in three days and, reverses viremia.
And, just a few small points:
Leronlimab has no exclusion criteria.
Leronlimab is a SQ injection
Leronlimab met a designated endpoint without the whole of the FDA rushing to move the goal posts once Gilead had already kicked the ball.
I just realized why the FDA is slow walking Cytodyn. They are still exhausted from moving the goalposts for Gilead remdesevir trial.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼